Transaction · 0001193125-26-436441

Kulkarni Samarth

Kulkarni Samarth, CEO, reported a transaction classified as grant at CRISPR Therapeutics AG involving 57500.000000 shares for an estimated $0.00. Reported holdings after the transaction were 57500.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ACEO
CRSPCRISPR Therapeutics AG
Trade date
Oct 26, 2026
Filing date
Oct 28, 2026
View on SEC Insider profile
Disclosed value$0Shares × reported price
Shares traded57.5k$0.00 per share
Holdings after57.5kDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

CRSP price since this filing

Daily closing prices, with the filing date and available return windows
CRSP · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +0.2%1w ago -7.5%1d ago -8.7%
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0001193125-26-436441
Stock Option (Right to Buy)
Transaction date
Oct 26, 2026
Filed Oct 28, 2026, 09:38 PM · 2d delay
Shares
57,500 sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
57,500 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Direct Ownership Large Holdings Increase
Filing-only score

-6 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
  • derivative_transaction-16 points

    is_derivative = true

    Derivative exercise rows are less discretionary than open-market purchases.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Executive Officer

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    This option was granted on October 26, 2026 with respect to 57,500 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 26, 2026.

  2. F2

    Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

  3. F3

    This restricted stock unit award was granted on October 26, 2026 with respect to 28,750 Common Shares, with (i) one quarter of the shares vesting on October 26, 2027, (ii) one quarter of the shares ve…

Original filing · 0001193125-26-436441
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

CRSP